About the Company
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on C4 Therapeutics, Inc.
Spotlight On 3 Intriguing Penny Stocks With Market Caps As Low As $100M
As major U.S. indices rebound with solid weekly gains, investors are turning their attention to various opportunities within the market. Penny stocks, despite their somewhat outdated name, continue to ...
C4 Therapeutics Advances in Protein Degradation Therapy
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies, primarily within the oncology sector. The company aims to ...
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting ...
Forward-Looking Statements This press release contains “forward-looking statements” of C4 Therapeutics, Inc. within the meaning of the Private Securities Litigation Reform Act of 1995.
What's Going On With C4 Therapeutics Stock?
C4 Therapeutics, Inc. CCCC shares are trading higher Friday, and the stock has gained more than 350% over the past five days. Here's a look at what's going on: What To Know: ...
Sei Investments Co. Purchases New Shares in C4 Therapeutics, Inc ...
C4 Therapeutics, Inc. has a 1 year low of $1.09 and a 1 year high of $8.08. The company has a market cap of $88.03 million, a price-to-earnings ratio of -0.73 and a beta of 3.11.
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.26 per share a year ago. These ...
C4 Therapeutics Stock Is Surging Wednesday: What's Going On?
C4 Therapeutics Inc CCCC shares are trading higher Wednesday after the company presented data from a Phase 1 trial for the potential treatment of multiple myeloma. What Happened: C4 Therapeutics ...
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue ... - Nasdaq
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.74. This compares to loss of $0.56 per share a year ago.
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue ... - Nasdaq
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.68 per share a year ago.
Similar Companies
Loading the latest forecasts...